Literature DB >> 29317335

Integrated case-control and somatic-germline interaction analyses of melanoma susceptibility genes.

Yao Yu1, Hao Hu1, Jiun-Sheng Chen2, Fulan Hu3, Jerry Fowler1, Paul Scheet1, Hua Zhao1, Chad D Huff4.   

Abstract

While a number of genes have been implicated in melanoma susceptibility, the role of protein-coding variation in melanoma development and progression remains underexplored. To better characterize the role of germline coding variation in melanoma, we conducted a whole-exome case-control and somatic-germline interaction study involving 322 skin cutaneous melanoma cases from The Cancer Genome Atlas and 3607 controls of European ancestry. We controlled for cross-platform technological stratification using XPAT and conducted gene-based association tests using VAAST 2. Four established melanoma susceptibility genes achieved nominal statistical significance, MC1R (p = .0014), MITF (p = .0165) BRCA2 (p = .0206), and MTAP (p = .0393). We also observed a suggestive association for FANCA (p = .002), a gene previously implicated in melanoma survival. The association signal for BRCA2 was driven primarily by likely gene disrupting (LGD) variants, with an Odds Ratio (OR) of 5.62 (95% Confidence Interval (CI) 1.03-30.1). In contrast, the association signals for MC1R and MITF were driven primarily by predicted pathogenic missense variants, with estimated ORs of 1.4 to 3.0 for MC1R and 4.1 for MITF. MTAP exhibited an excess of both LGD and predicted damaging missense variants among cases, with ORs of 5.62 and 3.72, respectively, although neither category was significant. For individuals with known or predicted damaging variants, age of disease onset was significantly lower for two of the four genes, MC1R (p = .005) and MTAP (p = .035). In an analysis of germline carrier status and overlapping copy number alterations, we observed no evidence to support a two-hit model of carcinogenesis in any of the four genes. Although MC1R carriers were represented proportionally among the four molecular tumor subtypes, these individuals accounted for 69% of ultraviolet (UV) radiation mutational signatures among triple-wild type tumors (p = .040), highlighting the increased sensitivity to UV exposure among individuals with loss-of-function variants in MC1R.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer susceptibility gene; Case-control study; Skin cutaneous melanoma; Somatic-germline interaction; Whole exome association analysis

Mesh:

Substances:

Year:  2018        PMID: 29317335      PMCID: PMC6501568          DOI: 10.1016/j.bbadis.2018.01.007

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  6 in total

1.  Exome-Wide Pan-Cancer Analysis of Germline Variants in 8,719 Individuals Finds Little Evidence of Rare Variant Associations.

Authors:  Zoe Guan; Ronglai Shen; Colin B Begg
Journal:  Hum Hered       Date:  2021-10-29       Impact factor: 0.444

Review 2.  A Systematic Literature Review of Whole Exome and Genome Sequencing Population Studies of Genetic Susceptibility to Cancer.

Authors:  Alisa M Goldstein; Elizabeth M Gillanders; Melissa Rotunno; Rolando Barajas; Mindy Clyne; Elise Hoover; Naoko I Simonds; Tram Kim Lam; Leah E Mechanic
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

3.  Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients.

Authors:  Lauren G Aoude; Vanessa F Bonazzi; Sandra Brosda; Kalpana Patel; Lambros T Koufariotis; Harald Oey; Katia Nones; Scott Wood; John V Pearson; James M Lonie; Melissa Arneil; Victoria Atkinson; B Mark Smithers; Nicola Waddell; Andrew P Barbour
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

4.  Family-based whole-exome sequencing identifies rare variants potentially related to cutaneous melanoma predisposition in Brazilian melanoma-prone families.

Authors:  Felipe Fidalgo; Giovana Tardin Torrezan; Bianca Costa Soares de Sá; Bruna Durães de Figueiredo Barros; Luciana Facure Moredo; Renan Valieris; Sandro J de Souza; João Pereira Duprat; Ana Cristina Victorino Krepischi; Dirce Maria Carraro
Journal:  PLoS One       Date:  2022-01-27       Impact factor: 3.240

5.  Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.

Authors:  Honey Bokharaie; Walter Kolch; Aleksandar Krstic
Journal:  Biomolecules       Date:  2022-07-17

Review 6.  Germline Variants That Affect Tumor Progression.

Authors:  Ajay Chatrath; Aakrosh Ratan; Anindya Dutta
Journal:  Trends Genet       Date:  2020-11-14       Impact factor: 11.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.